Lung Cancer

Patients with certain lung and colorectal cancers whose physicians participated in weekly, treatment-focused tumor board meetings had improved survival and were 60% more likely to enroll in a clinical trial

Patients in one phase III trial gained 2.4 pounds of lean body mass during 12 weeks of treatment with anamorelin, and those in the second trial had an average increase in lean body mass of 1.65 pounds.

Lung cancer at any age is a catastrophic illness but it is particularly devastating when it affects young adults in the prime of their life.

New patient-reported data presented at the 2014 ASTRO Annual Meeting has shown that Manuka honey is not more effective than standard medical care for the treatment of esophagitis pain during radiation therapy.

Although lung cancer incidence is decreasing in the United States, the details about this trend are unknown.

Results of a large, pooled analysis indicate that there is a link between a number of common respiratory diseases and an increase in the risk of developing lung cancer.

Danielle Hicks, director, Patient Services and Support, Bonnie J. Addario Lung Cancer Foundation, discusses the lung cancer living room program

When the US Preventive Services Task Force (USPSTF) recommended last year that asymptomatic, high-risk individuals should receive annual screening for lung cancer with low-dose computed tomography (LDCT), it made a healthy decision for the American population.

The Addario Lung Cancer Medical Institute (ALCMI) today launched a new study, the Genomics of Young Lung Cancer, to understand why lung cancer occurs in young adults, who quite often are athletic, never smokers and do not exhibit any of the known lung cancer genetic mutations.

Five novel agents for the treatment of patients with advanced squamous cell carcinoma of the lung will be evaluated in the recently launched Lung-MAP trial, an innovative biomarker-driven study that aims to improve the drug development process while exploring therapeutic options for this challenging malignancy.

Scott Santarella, president, CEO, Bonnie J. Addario Lung Cancer Foundation, discusses some exciting updates in the field of lung cancer.

Fadlo R. Khuri, MD, FACP, professor, chair, hematology/medical oncology, Emory University School of Medicine, deputy director, Winship Cancer Institute, discusses survivorship in lung cancer.

Data on electronic cigarette, or e-cigarettes, suggests that sales are up and it's predicted that e-cigarette sales will exceed cigarette sales in the next decade.

The results of two phase III trials reported at the 2014 MASCC/ISOO International Symposium on Supportive Care in Cancer have found that enobosarm, a first-in-class, nonsteroidal, oral selective androgen receptor modulator (SARM), led to an increase in lean body mass (LBM) compared with a decline in LBM observed with placebo for patients with non-small cell lung cancer (NSCLC).

Back in 2005, the Surgeon General issued a health advisory about radon, the second leading cause of lung cancer in the United States and called it a completely preventable health threat.

Rebecca Lehto, PhD, RN, OCN, Assistant Professor, College of Nursing, Michigan State University, discusses symptom burden in lung cancer.

Leading experts in the rapidly evolving field of lung cancer treatment assembled for the 1st Annual Miami Lung Cancer Conferenceâ„¢ in Miami Beach, Florida, on March 8, to offer their perspectives on the latest research and provide clinical insights for practitioners dealing with challenging cases.

The FDA has granted an accelerated approval to the next-generation ALK inhibitor ceritinib as a treatment for patients with ALK-positive metastatic non-small cell lung cancer following progression on crizotinib.

I have been living with stage IV lung cancer for three years, not because I have the disease, but because my husband does.

The criteria that are presently used to determine whether patients with non-small cell lung cancer (NSCLC) may be suitable for treatment with the ALK inhibitor crizotinib may overlook some patients who may benefit from the drug, researchers report.

Nina Grenon, RN, APRN, BC, nurse practitioner, Dana-Farber Cancer Institute, discusses the results of a study that looked at the effect of palliative care in patients with lung cancer.

Differences in lung cancer incidence between men and women narrow with decreasing age.

More and more, as the use of maintenance therapy increases, oncology nurses are tasked with monitoring how the strategy is working for specific patients.

Using different selection criteria for screening is superior to currently recommended criteria.

Donna Berry, from the Dana-Farber Cancer Institute, Explains a Nurse-Led Education Program That Enhanced Oral Therapy Compliance.

The National Comprehensive Cancer Network releases newest update.

CAP is a nonprofit providing information, resource referrals for personal support, and public advocacy for people at risk for or living with lung cancer or hepatitis C.

Personal perspectives from oncology nurses of abstracts presented at ASCO on research with the potential to change practice, important studies that failed to meet expectations, and topics particularly relevant to oncology nurses.

Will graphic images and stronger warnings decrease cigarette smoking?

Negative attitudes toward smokers extend to patients with lung cancer, regardless of whether or not they have ever actually smoked